A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever).

Autor:	Messina JA; Duke University School of Medicine, Durham, NC, USA., Maziarz EK; Duke University School of Medicine, Durham, NC, USA., Galgiani J; Valley Fever Center for Excellence, University of Arizona, Tucson, AZ, USA., Truong JT; Southern California Kaiser Permanente, Antelope Valley, CA, USA., Htoo AK; Southern California Kaiser Permanente, Kern County, CA, USA., Heidari A; Valley Fever Institute, Kern Medical, Bakersfield, CA, USA., Johnson RH; Valley Fever Institute, Kern Medical, Bakersfield, CA, USA., Narang AT; Banner University Medical Center Phoenix, Phoenix, AZ, USA., Donovan FM; Banner University Medical Center Tuscon, Tuscon, AZ, USA., Ewell M; Emmes, Rockville, MD, USA., Catanzaro A; University of California San Diego Medical Center, San Diego, CA, USA., Thompson GR 3rd; University of California Davis School of Medicine, Sacramento, CA, USA., Ampel NM; University of Arizona, Tucson, AZ, USA., Perfect JR; Duke University School of Medicine, Durham, NC, USA., Naggie S; Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Walter EB; Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.; Duke Human Vaccine Institute, Durham, NC, USA.
Jazyk:	angličtina
Zdroj:	Contemporary clinical trials communications [Contemp Clin Trials Commun] 2021 Oct 14; Vol. 24, pp. 100851. Date of Electronic Publication: 2021 Oct 14 (Print Publication: 2021).
DOI:	10.1016/j.conctc.2021.100851
Abstrakt:	Introduction: Coccidioidomycosis is a fungal infection endemic in the southwestern United States (US). Primary pulmonary coccidioidomycosis (PPC) is a leading cause of community-acquired pneumonia (CAP) in this region, although its diagnosis is often delayed, leading to lag in antifungal treatment and subsequent morbidity. The impact of early empiric antifungal therapy as part of treatment for CAP in endemic areas on clinical outcomes is unknown. Methods: Phase IV randomized, double-blind, placebo-controlled trial in individuals aged 18 years or older with CAP who met all eligibility criteria in Coccidioides endemic regions in the US. Eligible participants with CAP were randomized to receive either fluconazole (400 mg daily) or matching placebo for 42 days and were subsequently monitored for clinical resolution of their illness. Objectives: The primary objective was to assess the clinical response of early empiric antifungal therapy with fluconazole through Day 22 in subjects with PPC who were adherent to the study intervention. Secondary objectives included: assessments of the impact of early empiric antifungal therapy with fluconazole through Day 22 and 43 in subjects with PPC regardless of adherence, comparisons of the clinical response and its individual components over time by treatment group in subjects with PPC, assessments of days lost from work or school, hospitalization, and all-cause mortality. Discussion: This trial was halted early due to slow enrollment (72 participants in one year, 33 received fluconazole and 39 received placebo). Of those enrolled, eight (11%) met the study definition of PPC. The study design and challenges are discussed. Competing Interests: Julia A. Messina, MD, MHS, MSc: Nothing to report. Eileen K. Maziarz, MD: Nothing to report. John Galgiani, MD: Nothing to report. Jonathan T. Truong, MD: Nothing to report. Aung K. Htoo, MD: Nothing to report. Arash Heidari, MD: Nothing to report. Royce H. Johnson, MD: Nothing to report. Aneesh T. Narang, MD: Nothing to report. Fabria M. Donovan, MD, PhD: Nothing to report. Marion Ewell, ScD: Nothing to report. Antonino Catanzaro, MD: Nothing to report. George R. Thompson III, MD: Nothing to report. Neil M. Ampel, MD: Nothing to report. John R. Perfect, MD: reports research grants and consultation from the following: Astellas, Pfizer, Merck, Amplyx, Scynexis, Matinas, F2G, Appili and Minnetronix. Susanna Naggie, MD, MHS: Nothing to report. Emmanuel B. Walter, MD, MPH: has served as an investigator for clinical trials funded by Moderna and Pfizer. (© 2021 Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu